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Pyruvate kinase deficiency in a South African kindred 
caused by a 1529A mutation in the PK-LR gene 
Pierre M Durand, Theresa L Coetzer
To the Editor: There is currently no investigation for pyruvate 
kinase (PK) deficiency in South Africa and nothing is known 
about local mutations. We describe the implementation of 
a PK assay and document the first mutation underlying PK 
deficiency in a South African patient who presented with a 
haemolytic episode following ARV (antiretroviral) prophylaxis.
PK deficiency is the most common inherited disorder of 
glycolysis in humans.1 The enzyme catalyses the conversion 
of phosphoenolpyruvate (PEP) to pyruvate, producing 
adenosine triphosphate (ATP) from adenosine diphosphate 
(ADP) in the process. A PK deficiency therefore results in 
decreased intra-erythrocytic ATP, which cannot be compensated 
for by oxidative phosphorylation since erythrocytes lack 
mitochondria. This leads to membrane damage, haemolysis 
and premature destruction in the spleen.
Epidemiological studies indicated that the PK heterozygote 
allele frequency ranges from 1% to 5% in Caucasian 
populations, and one small study suggested the frequency 
might be twice as high in African-Americans.2 Areas of 
south-east Asia may have a significantly higher prevalence,2,3 
although there have been no large-scale studies conducted in 
this region. The reason for the relatively high frequency of the 
abnormal PK allele has been debated. The majority of inherited 
erythrocyte disorders have been selected by their relative 
resistance to malaria,4 and we have recently demonstrated that 
PK deficiency protects against malaria in humans (manuscript 
accepted for publication in Haematologica, May 2008), which 
provides a possible explanation.
The prevalence of the disease in South Africa is unknown, 
and few individual cases have been reported (personal 
communication, Dr N Alli, Chris Hani Baragwanath Hospital). 
There is currently no available assay for PK deficiency in South 
Africa, and nothing is known about the underlying mutations 
in the PK-LR gene in South Africans and Africans in general. 
More than 180 mutations cause the disease,3 and it would be 
interesting to establish the mutation spectrum in southern 
Africans.
We report the implementation of an assay for PK activity. A 
patient with suspected PK deficiency was confirmed to have 
the disease, and the underlying mutation was identified.
Methods
PK assay implementation
The PK assay, based on Beutler’s method5 with a few minor 
modifications, was implemented in the Red Cell Membrane 
Unit, Department of Molecular Medicine and Haematology 
at the University of the Witwatersrand National Health 
Laboratory Service (NHLS) in Johannesburg. Qualitative 
(screening) and quantitative (confirmatory) assays were 
implemented, and the screening assay may be added to the 
routine tests offered by the NHLS. Guidelines for physicians 
are available from the authors.
The screening and quantitative assays use the same test 
principle: Plasma and leucocytes are removed from whole 
blood and the packed erythrocytes resuspended in 0.9% 
saline. A 1:20 haemolysate is made of the red cells and used 
to determine PK enzyme activity by the conversion of PEP to 
pyruvate. This reaction is coupled to a second reaction, which 
uses lactate dehydrogenase to convert pyruvate to lactate with 
nicotinamide adenine dinucleotide (reduced form) (NADH) 
as a co-factor. The oxidation of NADH is determined by a loss 
of fluorescence (screening assay) or spectrophotometrically at 
340 nm (quantitative assay), and is used as a measure of PK 
activity.
Ethics clearance was obtained from the Human Research 
Ethics Committee (Medical), of the University of the 
Department of Molecular Medicine and Haematology, University of the Witwa-
tersrand and National Health Laboratory Service (NHLS), Johannesburg
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Witwatersrand to analyse EDTA blood samples from 20 
whites and 20 blacks with haematologically normal profiles, to 
determine a local reference range for PK activity. The following 
quality assurance issues were addressed: assay precision and 
reproducibility; assay sensitivity; enzyme stability in whole 
blood; paediatric samples; and feasibility to implement the 
assay as a routine test. The assay was validated with blood 
from a PK-deficient patient.
Mutation analysis
DNA mutation analysis was performed on samples from the 
PK-deficient patient and 1 parent. In brief, genomic DNA 
was extracted from the buffy coat6 and exons 8-10, 11 and 12 
of the PK-LR gene amplified by polymerase chain reaction 




The screening assay detected a decreased PK activity if the 
sample had an enzyme activity of <50% of the mean. This is 
considered adequate, since clinically relevant PK deficiency 
develops when an individual has an enzyme activity of <25% 
of normal.
There was no difference between the means of the white 
(13.41 U/g haemoglobin (Hb)) and black (12.64 U/g Hb) 
groups (p=0.29). The combined mean (± significant deviation 
(SD)) (N=40) in this study was 13.01±2 U/g Hb and falls 
within 1 SD of the published reference range.1 The coefficient 
of variation for the precision and reproducibility of the 
quantitative assay was 5%. The PK enzyme is stable in EDTA 
whole blood for 5 days if stored at 4oC, and for 3 days if stored 
at room temperature. The minimum volume of whole blood 
required to perform the assay is 0.5 ml, which makes it suitable 
for samples taken from paediatric patients. The assay was 
performed on a further 10 samples received from laboratories 
around the country as part of a ‘haemolytic work-up’ to 
demonstrate the applicability and feasibility of the assay in a 
routine setting.
PK-deficient patient
A 24-year-old white woman with suspected PK deficiency 
had suffered a haemolytic episode immediately after the 
prophylactic use of antiretrovirals (3TC, AZT and Crixivan) a 
year earlier. A referral letter reported haemolytic episodes as 
an infant but nothing subsequently. The only medication she 
used was Sibelium for migraines, and she was otherwise well. 
She was jaundiced and had no clinically evident splenomegaly. 
At the time of referral, her serum Hb was 9.6g/dl and she had 
a reticulocytosis (15.6%). The quantitative PK assay confirmed 
the enzyme deficiency. The patient’s mean PK activity 
was 15% of normal (N=4). One parent was identified as an 
asymptomatic carrier and had an enzyme activity of 58% of 
normal (N=3). The second parent was unavailable.
The association between haemolytic crises in PK deficiency 
and ARVs has not been reported in the literature previously, 
and this finding is important in South Africa.
Mutation analysis
The patient was homozygous for the 1529A mutation in 
exon 11 in the PK-LR gene (Fig. 1). This is the most common 
mutation in northern Europeans and the first mutation 
described in a South African patient. The parent was 
heterozygous for the same mutation, which results in an amino 
acid change from arginine to glutamine at residue 510.
The authors thank the PK-deficient patient and her parent for their 
co-operation, and Drs I Thompson and P Keene for the referral.
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Fig. 1. Mutation analysis of the PK-deficient patient and parent. 
(a) Sequence data for the PK-deficient patient who is homozygous for the 
1529A mutation in the PK-LR gene and heterozygous parent. (b) A model 
of the mutant protein was generated with SWISS-PDB Viewer (http://
www.expasy.org/spdbv). The Arg510Gln mutation is not adjacent to the 
catalytic site, but the mutation decreases the activity and thermal stability 
(data not shown) of the mutant enzyme.
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